Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetravalent dengue prM-E mRNA-LNP vaccine
- Development stage
- Preclinical
- Lead developer
- University of Pennsylvania
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intradermal, Intramuscular
01
Overview
The tetravalent dengue prM-E mRNA-LNP vaccine is a preclinical-stage vaccine candidate designed to protect against all four serotypes of the dengue virus (DENV1, DENV2, DENV3, and DENV4). Developed by researchers at the Yale School of Medicine and the University of Pennsylvania, the vaccine consists of nucleoside-modified mRNAs encoding the pre-membrane (prM) and envelope (E) structural proteins of each of the four DENV serotypes, encapsulated within lipid nanoparticles (LNPs). In preclinical mouse models, the vaccine has been shown to elicit robust neutralizing antibody responses against all four serotypes and to induce germinal center B cell activity and tissue-resident memory T (Trm) cells, particularly when administered via intradermal delivery.
- Other names
- tetravalent DENV prM-E mRNA-LNP vaccinetetravalent dengue prM-E mRNA-LNP vaccinetetravalent prM-E mRNA-LNP vaccine
02
Targets
E (Tick-borne encephalitis virus envelope protein)prM (Zika virus precursor membrane protein)
Beyond the preview
Go deeper on tetravalent dengue prM-E mRNA-LNP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetravalent dengue prM-E mRNA-LNP vaccine.